Table 1:
Baseline characteristics
| Characteristic | n (%)* | p | |
|---|---|---|---|
| Current alcohol use (n = 217) | No current alcohol use (n = 508) | ||
| Male sex | 149 (69) | 327 (64) | 0.26 |
| Age, y, mean (SD) | 54.5 (11.9) | 51.2 (12.9) | <0.01 |
| Race† | 0.03 | ||
| White | 160 (80) | 353 (78) | |
| Black | 11 (6) | 10 (2) | |
| East Indian | 7 (4) | 22 (5) | |
| South East Asian | 3 (2) | 26 (6) | |
| Indigenous | 6 (3) | 21 (5) | |
| Other | 7 (4) | 22 (5) | |
| Genotype‡ | 0.10 | ||
| 1a | 96 (45) | 239 (49) | |
| 1b | 36 (17) | 55 (11) | |
| 1 other subtype | 5 (2) | 9 (2) | |
| 2 | 30 (14) | 42 (9) | |
| 3 | 42 (20) | 124 (26) | |
| 4 | 3 (1) | 12 (2) | |
| 6 | 2 (<1) | 5 (1) | |
| Fibrosis stage§ | 0.81 | ||
| F1 | 80 (42) | 178 (39) | |
| F2 | 43 (23) | 94 (21) | |
| F3 | 25 (13) | 64 (14) | |
| F4 | 43 (23) | 115 (25) | |
| Antiviral treatment naive¶ | 83 (71) | 201 (68) | 0.52 |
| Initiated a DAA regimen** | 179 (82) | 417 (82) | 0.99 |
| SVR (intent-to-treat)†† | 140 (94) | 272 (92) | 0.45 |
Note: Percentages may not total 100 because of rounding
*
Unless otherwise indicated
†
ns = 194 and 454 for current alcohol use and no current alcohol use, respectively
‡
ns = 214 and 486 for current alcohol use and no current alcohol use, respectively
§ ns = 191 and 451 for current alcohol use and no current alcohol use, respectively
¶ ns = 117 and 297 for current alcohol use and no current alcohol use, respectively
**
ns = 217 and 508 for current alcohol use and no current alcohol use, respectively
††
ns = 149 and 297 for current alcohol use and no current alcohol use, respectively
DAA = Direct-acting antiviral; SVR = Sustained virological response